Comparison of Visual Fields: Humphrey Field Analyzer (HFA) SITA Strategy, SCOPE (GATE Strategy) and Humphrey MATRIX Perimeter (X-SCOPE)

University Hospital Tuebingen

Status: Unknown

Conditions: Glaucoma

Treatments: Device: three different perimeters: HFA, Octopus, MATRIX

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01068938

116MIR08023 (Other Grant/Funding Number)

X-SCOPE

428/2008BO1 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to compare three perimetric techniques regarding progression of the visual field.

Enrollment: 30 estimated patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• max. ± 8 dpt sph, max. ± 3 dpt cyl
• distant visual acuity > 10/20
• isocoria, pupil diameter > 3 mm
• at least one risk of progression: optic disc (splinter) hemorrhage / cup to disc ratio (CDR) > 0.7 / inter-eye asymmetry of CDR >0.2 / notching of the optic disc /retinal nerve fibre layer (RNFL) defects / intraocular pressure( IOP) >22 mmHg / central corneal thickness < 520 µm / advanced visual field defect stage Aulhorn III / elder than 70 years

Exclusion criteria

• pregnancy, nursing
• diabetic retinopathy
• asthma
• HIV+ or AIDS
• history of epilepsy or significant psychiatric disease
• medications known to effect visual field sensitivity
• infections (e.g. keratitis, conjunctivitis, uveitis)
• severe dry eyes
• miotic drug
• amblyopia
• squint
• nystagmus
• albinism
• any ocular pathology, in either eye, that may interfere with the ability to obtain visual fields,disc imaging or accurate IOP readings
• keratoconus
• intraocular surgery (except for uncomplicated cataract surgery) performed < 3 month prior to screening
• history or signs of any visual pathway affection other than glaucoma
• allergies with regard to topic glaucoma medication
• history or presence of macular disease and / or macular edema
• ocular trauma
• medications known to affect visual field sensitivity

Trial design

30 participants in 1 patient group

open angle glaucoma, glaucoma suspects

Description:

risk of progression, Latanoprost monotherapy

Treatment:

Device: three different perimeters: HFA, Octopus, MATRIX